Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Catheter Precision ( (VTAK) ) just unveiled an update.
On February 6, 2026, Catheter Precision entered into a securities purchase agreement with accredited investors for a private placement of common stock and several new series of convertible preferred stock, initially raising about $2.18 million and setting up additional tranches that could significantly expand the financing subject to shareholder and regulatory approvals. The company plans to use the proceeds to repay debt, fund general corporate and working-capital needs, and, critically, to unwind or restructure its legacy catheter business, settle legacy liabilities, and simplify its capital structure, indicating a strategic pivot in its operations and public-company profile. In a parallel move on the same date, Catheter Precision agreed to acquire a 19.98% stake in Fly Flyte, Inc. from SEG Jets LLC for $5.25 million in newly issued Series D convertible preferred stock, further tying its future to the luxury regional air-mobility market. The company also amended existing Series B preferred stock and warrant terms via a letter agreement on February 6, 2026, lowering exercise and conversion prices in exchange for immediate warrant exercises and conversion, delivering roughly $0.4 million in cash and consolidating ownership into common stock, which supports liquidity while diluting existing shareholders and reshaping the equity base.
The most recent analyst rating on (VTAK) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Catheter Precision stock, see the VTAK Stock Forecast page.
Spark’s Take on VTAK Stock
According to Spark, TipRanks’ AI Analyst, VTAK is a Neutral.
The score is primarily weighed down by weak financial performance driven by very large ongoing losses and significant cash burn, despite improving revenue. Technicals add additional pressure as the stock trades below major moving averages with negative MACD. Valuation contributes limited support because losses make P/E less informative and no dividend yield is available.
To see Spark’s full report on VTAK stock, click here.
More about Catheter Precision
Catheter Precision, Inc. operates as a public medical technology company that historically focused on a catheter-based business. The company is now moving to unwind, divest, or otherwise restructure this legacy catheter operation, aiming to reduce operating expenses and cash burn and reposition itself as a streamlined public company with a simplified balance sheet. It is also entering the luxury regional air-mobility space through an equity stake in Fly Flyte, Inc., a rapidly scaling private aviation firm that uses AI-driven operations and a growing fleet of Vision Jets for short‑haul private flights.
Average Trading Volume: 36,835
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.12M
See more insights into VTAK stock on TipRanks’ Stock Analysis page.